Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23245465 | 1.00 | LMNA (0.43) | LMNACYP2C9CHRM2CHRM1CHRM3 | |
| SCHEMBL23245462 | 1.00 | LMNA (0.43) | LMNACYP2C9CHRM2CHRM1CHRM3 | |
| SCHEMBL10361267 | 0.78 | SLC6A2 (0.43) | LMNACYP2C9CHRM1 | |
| SCHEMBL18716619 | 0.78 | FUCA1 (0.35) | FUCA1 | |
| SCHEMBL23245642 | 0.78 | TDP1 (0.35) | FUCA1 | |
| SCHEMBL23245679 | 0.78 | TDP1 (0.35) | FUCA1 | |
| Hydrochloric Acid SCHEMBL11056736 | 0.77 | SLC6A2 (0.42) | LMNACYP2C9CHRM1 | |
| SCHEMBL18716576 | 0.75 | CACNA1H (0.31) | FUCA1 | |
| SCHEMBL18716685 | 0.72 | CACNA1H (0.30) | — | |
| SCHEMBL21358491 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319698-B2 | Proteasome activity enhancing compounds | Kineta, Inc. (US) | 2025-06-03 | — | — | US | disclosed |
| US-20230183256-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | YUMANITY THERAPEUTICS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-11560385-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210115057-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115057-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSME3, PSMC4 | LMNA 1575/4885CYP2C9 2804/4885CHRM2 4601/4885 |
| US-11560385-B2 | Proteasome activity enhancing compounds | PSMG3, PSME3, PSMC4 | LMNA 1575/4885CYP2C9 2804/4885CHRM2 4601/4885 |
| US-12319698-B2 | Proteasome activity enhancing compounds | PSMG3, PSME3, PSMC4 | LMNA 1575/4885CYP2C9 2804/4885CHRM2 4601/4885 |
| US-20230183256-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSME3, PSMC4 | LMNA 1575/4885CYP2C9 2804/4885CHRM2 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.